Chief Scientific Officer Appointment
We are pleased to announce a significant addition to Triple Hair's management team with the appointment of Dr. Satish Asotra, Ph.D., MBA, as Chief Scientific Officer of the Company.
Triple hair announces the appointment of its chief scientific officer

Satish is a senior executive and strategic leader with a proven track record of driving pharmaceutical development, innovation and process improvement with 25 years of experience, including more than 12 years in topical and dermatological product development. Prior to joining Triple Hair, he was Senior Vice President at Avicanna, where he was in-charge of Scientific Affairs and Quality as well as Vice President of R&D. He led a multidisciplinary team and provided leadership to the scientific team that developed pharmaceutical/healthcare products, prepared CMC packages and filed regulatory dossiers for clinical studies. During his extensive scientific career, he also held the positions of Chief Scientific Officer at AHI, Senior Director of Research and Development at Accucaps, and Vice President of Research and Development at Odan Laboratories and Taro Pharmaceuticals.

Satish has also published more than 35 research papers and written numerous review articles. He is a co-inventor of 12 awarded patents and has filed a patent in the United States in 2019 on a unique topical cannabis formulation with pharmaceutical application. Satish has an MBA from the Ivey Business School and a Ph.D. in Animal Science (Physiology and Biochemistry) from H.P.A University in Palampur, India.

We are proud to have been able to attract a person of Satish’s caliber to Triple Hair.

In addition to his impressive scientific background, Satish has the expertise and know-how required to take our innovative TH07 product from Phase 3 clinical trials to the commercial phase. In particular, his vast experience in the development of topical and dermatological products, the conduct of clinical studies with Health Canada and the FDA (including Section 505(b)2) and the successful commercialization of several major pharmaceutical products will most certainly enable Triple Hair to achieve its objectives for TH07, TH16 and TH18. Satish’s mandate will also include the development of other promising products to maximize shareholder value.

Triple hair new corporate presentation

I would like to thank the people who attended the presentations in Moncton on January 23 and 25. It was a real pleasure to be able to meet with you and talk about Triple Hair’s accomplishments and our plans for the future.

Here is a copy of Triple Hair’s

We are also pleased to report that the second round of financing is progressing well. We anticipate raising the targeted amount and expect to complete the financing by the end of February.

Please contact me if you need more information about Triple Hair.